Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival - Takeaways - MDSpire

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

  • By

  • Yating Wu

  • Hang Li

  • Yonghai Peng

  • Weiqiang Fan

  • June 1, 2026

  • 0 min

Share

  • 1

    A 60-year-old male with extensive-stage small-cell lung cancer and brainstem metastasis achieved over 20 months of disease-free survival after TMEp-CI-M treatment.

  • 2

    The TMEp-CI-M platform includes tumor microenvironment priming, checkpoint inhibition, and microbiome modulation to enhance immunotherapy efficacy.

  • 3

    The patient's pro-gastrin-releasing peptide level normalized after the first treatment cycle, indicating a positive response to the therapy.

  • 4

    Only Grade 1 hypothyroidism was reported as an adverse event during the treatment, suggesting a favorable safety profile.

  • 5

    The case supports further investigation of the TMEp-CI-M platform in treating extensive-stage small-cell lung cancer with brain metastases.

Original Source(s)

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

  • by Yating Wu, Hang Li, Yonghai Peng, Weiqiang Fan

  • June 1, 2026

Related Content

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Total ureteral replacement with a small intestinal graft as a reconstructive stage of combined treatment for recurrent colorectal cancer: case report